A 2-year-old boy from rural Maharashtra presents with leukocoria (white pupil reflex) in the left eye noticed by his mother 3 weeks ago. On examination, the child is otherwise healthy with no systemic features. Dilated fundoscopy shows a whitish intraocular mass in the posterior pole. What is the most appropriate next step in management?

Explanation

## Clinical Scenario Assessment A 2-year-old with unilateral leukocoria and a posterior pole mass is highly suspicious for retinoblastoma. The child requires urgent but systematic evaluation before definitive treatment. ## Why Referral to Tertiary Centre is the Correct Next Step **Key Point:** Retinoblastoma management requires multidisciplinary expertise (pediatric oncology, ocular oncology, imaging specialists) and staging investigations before any irreversible treatment. **High-Yield:** The first step after clinical suspicion is NOT treatment—it is **accurate staging and risk stratification**. This determines whether the eye can be salvaged (globe-sparing therapy) or must be enucleated. ### Essential Pre-Treatment Workup 1. **Imaging for local staging:** - MRI orbit (preferred over CT to avoid radiation in a child; shows intraocular mass, optic nerve involvement, extraocular extension) - B-scan ultrasonography (if MRI contraindicated) 2. **Systemic staging:** - Lumbar puncture with CSF cytology (CNS involvement) - Bone marrow aspiration/biopsy (metastatic disease) - Chest CT (pulmonary metastases) - Genetic testing (RB1 mutation; identifies heritable cases requiring bilateral screening) 3. **Contralateral eye assessment:** - Dilated fundoscopy under anesthesia (rules out bilateral disease in ~5% of unilateral cases) **Clinical Pearl:** Retinoblastoma is classified as **intraocular (group A–E, International Classification)** or **extraocular** based on imaging. This classification, not the clinical appearance alone, guides treatment choice (chemoreduction, radiation, laser, cryotherapy, or enucleation). ## Why Each Distractor is Wrong | Option | Why Incorrect | |--------|---------------| | **Immediate enucleation** | Premature. Enucleation is reserved for advanced intraocular disease (group D–E) or eyes with no light perception. Staging may reveal a smaller, salvageable tumor. Removing an eye without staging is irreversible and may be unnecessary. | | **Systemic chemotherapy first** | Chemotherapy is used as neoadjuvant therapy in specific scenarios (e.g., group C–E, extraocular disease, or bilateral disease), but it is NOT the first step. Staging must precede all treatment decisions. | | **Observation with serial fundoscopy** | Dangerous. Retinoblastoma is a rapidly progressive malignancy with risk of metastasis and death if untreated. Observation is never appropriate once the diagnosis is suspected. | ## Management Algorithm ```mermaid flowchart TD A[Leukocoria + fundoscopic mass]:::outcome --> B[Refer to tertiary ocular oncology centre]:::action B --> C[Staging investigations: MRI, USG, CSF, BM, CXR, genetic testing]:::action C --> D{Intraocular disease classification?}:::decision D -->|Group A-B| E[Chemoreduction + focal therapy]:::action D -->|Group C| F[Chemoreduction ± radiation/laser]:::action D -->|Group D-E| G[Neoadjuvant chemotherapy then re-assess]:::action G --> H{Response to chemotherapy?}:::decision H -->|Good| I[Focal therapy/radiation]:::action H -->|Poor| J[Enucleation]:::action E --> K[Salvage eye]:::outcome J --> L[Histopathology + adjuvant therapy if needed]:::action ``` **Key Point:** Tertiary referral is the **standard of care** for all suspected retinoblastoma. It ensures accurate diagnosis (rule out mimics: toxoplasmosis, Coats disease, persistent fetal vasculature), staging, and risk-adapted treatment.